WO2025233861 - LONG-ACTING IL-15 AGONIST FOR TREATING TUMOR
National phase entry is expected:
Publication Number
WO/2025/233861
Publication Date
13.11.2025
International Application No.
PCT/IB2025/054796
International Filing Date
07.05.2025
Title **
[English]
LONG-ACTING IL-15 AGONIST FOR TREATING TUMOR
[French]
AGONISTE D'IL-15 À ACTION PROLONGÉE POUR LE TRAITEMENT DE TUMEUR
Applicants **
SUZHOU FORLONG BIOTECHNOLOGY CO., LTD.
Inventors
JI, En
WEI, Duo
Priority Data
PCT/CN2024/091740
08.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2193 | |
| EPO | Filing, Examination, Granting | 10009 | |
| Japan | Filing, Examination, Granting | 2275 | |
| South Korea | Filing, Examination, Granting | 2228 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,445
Contact Us
Abstract[English]
Described are agonistic IL-15 complexes for use in methods of treating diseases, such as solid tumors, in a human subject. The IL-15 complex contains an IL-15 and a fusion protein having an IL-15 receptor α sushi domain fused to an Fc monomer. The treatment results in an effective treatment of the diseases, without inducing treatment related serious adverse event.[French]
L'invention concerne des complexes agonistes d'IL-15 destinés à être utilisés dans des méthodes de traitement de maladies, telles que des tumeurs solides, chez un sujet humain. Le complexe d'IL-15 contient une IL-15 et une protéine de fusion ayant un domaine alpha sushi du récepteur IL-15 fusionné à un monomère Fc. Le traitement permet de traiter efficacement les maladies, sans induire d'événements indésirables graves.